By Jonathan Randles | Bloomberg
Eiger Biopharmaceuticals Inc., a company developing therapies for rare metabolic diseases, has filed for bankruptcy.
Publicly traded Eiger listed about $38.8 million in assets and $53.1 million in liabilities in a Chapter 11 petition filed Monday in Dallas. The bankruptcy filing will give Eiger time to discuss restructuring options with its creditors.
The stock fell as much as 51% after Bloomberg reported the filing. In bankruptcy, equity is last in line for repayment and shareholders are usually wiped out.
Related Articles
Amazon’s pharmacy will offer same-day delivery in LA and NYC and plans to expand
SEC tests insider-trading theory at trial of ex-Bay Area biotech executive
Mifepristone access is coming before the US Supreme Court. How safe is this abortion pill?
Why COVID patients who could most benefit from Paxlovid still aren’t getting it
Fact check: Biden is right. The US generally pays double that of other countries for prescription drugs
Eiger, based in Palo Alto, California, filed Chapter 11 after its board of directors explored other financing options including searching for equity financing, according to court documents. The company said it develops therapies for hepatitis delta virus and other serious diseases.
Eiger said in court papers it will attempt to sell its assets in Chapter 11.
More stories like this are available on bloomberg.com
©2024 Bloomberg L.P.
